Bayer VP elected to two of the firm’s executive committees
pharmafile | April 12, 2019 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Bayer, appointment
Dr Monika Lessl has been appointed to Bayer Foundations’ executive committee, selected by the German pharmaceutical firm’s Board of Management to lead both the Bayer Science Foundation and the Bayer Cares Foundation.
Her new leadership roles will be merged with her current responsibilities as Vice President, Head of Corporate Innovation and R&D at the firm.
Described by the company as “a cornerstone of Bayer’s societal engagement”, the Bayer Science Foundation aims to facilitate the development of research, nurture scientific talent and improve science education, the Bayer Cares Foundation focuses on employee engagement and social innovation.
“We are pleased to welcome Monika Lessl to the Foundation’s Executive Committee,” remarked Kemal Malik, Board Member for Innovation at Bayer. “With her broad expertise in science, social innovation and foundation-leadership, Monika will further advance the Foundations’ mission in driving excellence in science and promoting social progress.”
Dr Lessl has previously served at Bayer’s pharmaceutical division in Berlin as Head of External Innovation Therapeutics, where she oversaw the company’s innovation strategy and partnerships. Prior to this, she was CEO of the Ernst Schering Foundation, and she is currently also a Vice Chair on the Supervisory Board of the Futurium museum in Berlin.
“I feel honoured to join the Foundation’s executive committee”, commented Lessl. “The foundations offer a unique opportunity in shaping the future by nurturing new and emerging fields in science, driving social progress by working with social entrepreneurs and fostering the dialogue with all stakeholders on role and impact of innovation for the progress of our society.”
Related Content
Evotec and Bayer announce new kidney disease study
Evotec and Bayer have announced the initiation of a phase 2 clinical study in kidney …
Third application for Orion’s prostate cancer drug submitted by partner Bayer
Finnish pharmaceutical company Orion has announced that its partner Bayer is applying for a third application …
David Wheadon appointed to board of directors at Seaport Therapeutics
This week, Seaport Therapeutics have appointed David Wheadon MD to their board of directors.
